Skip to content
HowShorted

Iovance Biotherapeutics, Inc. short interest in 2020

In 2020, Iovance Biotherapeutics, Inc.'s disclosed short interest ran from 11.50% of shares outstanding on 15 Jan 2020 to 10.59% on 31 Dec 2020, a change of -0.91 percentage points. The year's high was 11.70% on 31 Jan 2020 and its low 8.82% on 30 Sep 2020, averaging 10.80% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 23.20 days on 30 Nov 2020. Full history: Iovance Biotherapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Iovance Biotherapeutics, Inc. in 2020

2020 in figures

Start of year
11.50% (15 Jan 2020)
End of year
10.59% (31 Dec 2020)
Change
-0.91 pp
High
11.70% (31 Jan 2020)
Low
8.82% (30 Sep 2020)
Average
10.80%
Highest days to cover
23.20 (30 Nov 2020)
SEC filings marked
8

Every report in 2020

Iovance Biotherapeutics, Inc. short interest in 2020
SettlementShort interestDays to coverFilings since previous
15 Jan 202011.50%10.02
31 Jan 202011.70%17.79
14 Feb 202011.14%20.81
28 Feb 202011.54%4.5710-K filed, results (8-K)
13 Mar 202010.16%5.82
31 Mar 202010.79%5.58
15 Apr 202011.19%9.84
30 Apr 202010.87%8.41
15 May 202010.81%8.8410-Q filed, results (8-K)
29 May 202011.26%8.27
15 Jun 202011.68%7.20
30 Jun 202011.54%4.71
15 Jul 202011.27%13.25
31 Jul 20209.53%17.23
14 Aug 20209.84%16.8310-Q filed, results (8-K)
31 Aug 20209.94%18.25
15 Sep 20209.48%12.36
30 Sep 20208.82%13.06
15 Oct 202010.35%5.83
30 Oct 202011.31%13.63
13 Nov 202011.30%16.8810-Q filed, results (8-K)
30 Nov 202011.44%23.20
15 Dec 202011.19%12.13
31 Dec 202010.59%12.09

See also: Iovance Biotherapeutics, Inc.'s full history · most shorted US stocks of 2020 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.